EarlySense, developer of continuous, contact-free supervision systems for hospital and home use, announced today the results of a clinical study of the EverOn(R) supervision system conducted at the Tel Aviv Medical Center, Sackler School of Medicine in Israel. The data were recently published by Drs. Patrick Sorkine, Nimrod Adi and Josef Ben-Ari at the European Respiratory Society Conference in Berlin in a presentation titled, New Device for Continuous and Contact-Free Monitoring of Heart and Respiratory Rates in Hospitalized Patients.
The objective of the study was to evaluate the accuracy of EverOn in comparison to standard ICU methods, for measuring heart and respirations rates and its ability to alert staff to significant changes. EverOn’s contact-free sensor was placed under the mattresses of more than 40 patient beds with the data displayed on EverOn’s control unit. The system continuously and automatically supervises patients without adding to the workload of the medical team. Patients were simultaneously monitored by the ICU’s standard of care monitors: ECG for heart rate and end tidal CO2 (= a gold standard) and impedance to measure respiration rate. Trained technicians also manually examined respiration rate.
EverOn’s advanced sensing and software technology was shown to provide the desired level of accurate readings while limiting the rate of false alerts. More specifically, when compared against the gold standard, the EverOn measured heart rates accurately over 92% of the time with an aRE=4.1% and respiration rates over 82% of the time with an aRE=7.7% . Moreover, EverOn’s accuracy in measuring respiration rate was higher than that of the standard monitor measurement, utilizing the thoracic impedance method with standard ECG leads. EverOn was found to be an easy to use and accurate tool for measuring respiration rate and heart rate in the critical care environment.
Dr. Adi said, “We are happy to have had the opportunity to share results that show that a contact-free system was able to conveniently and accurately measure respiratory and heart rates as well as provide timely identification of respiratory and cardiac related patient deteriorations. Study results show that continuous supervision of patients has the potential to significantly improve patient care.”
Dr. Ben Ari continued, “In addition to the potential benefit of a continuous supervision system on the medical/surgical floors, a system that measures respiratory rate accurately may also bring value for the care of non-intubated patients in the ICU environment. The EverOn also measures patient motion information, a measurement which may enhance patient care in the ICU and general care/acute care environments. Results of the EverOn motion analysis capability will be presented at upcoming scientific conferences.”
“Approximately 80% of patients in the general wards of hospitals are left unattended between rounds, especially at night when the hospital is short staffed. This situation increases the risk of potential safety events and crises for those hospitalized. Continuous supervision of vital signs has the potential to reduce such risks and improve the overall quality of care. The EverOn system is the next natural step in the ongoing efforts of hospitals to improve patient safety and quality of care. Contact-free, continuous supervision technology turns the hospital bed into a safe place,” said EarlySense CEO Mr. Avner Halperin.
About EarlySense
EarlySense is bringing to market a pioneering technology designed to advance proactive and preventive patient supervision to enable better patient outcomes. The company’s flagship product, EverOn, is an automatic, continuous, contact-free patient supervision device that follows and documents a patient’s movement and basic vital signs. The system is currently being clinically evaluated at several medical centers in the USA and Israel. EarlySense was founded in 2004 by experienced entrepreneurs and is headquartered in Ramat-Gan, Israel. For additional information, please visit www.earlysense.com or contact Marjie Hadad, Media Liaison, at +972-54-536-5220 or [email protected].
Comments